Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Purpose: Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation. The failure to completely ablate tissue androgens may limit suppression of PCa growth. We evaluated combinations of CYP17A and 5-α-reductase inhibitors for reducing prostate androgen levels, AR signaling, and PCa volumes. Patients and Methods: Thirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide and dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months before prostatectomy. Controls included patients receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide. The primary outcome measure was tissue dihydrotestosterone (DHT) concentration. Results: Prostate DHT levels were substantially lower in all experimental arms (0.02 to 0.04 ng/g v 0.92 ng/g in controls; P < .001). The ZBDK group demonstrated the greatest percentage decline in serum testosterone, androsterone, and dehydroepiandrosterone sulfate (P < .05 for all). Staining for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppressed in benign glands and moderately in malignant glands (P < .05 for all). Two patients had pathologic complete response, and nine had ≤ 0.2 cm 3 of residual tumor (defined as a near-complete response), with the largest numbers of complete and near-complete responses in the ZBDK group. Conclusion: Addition of androgen synthesis inhibitors lowers prostate androgens below that achieved with standard therapy, but significant AR signaling remains. Tissue-based analysis of steroids and AR signaling is critical to informing the search for optimal local and systemic control of high-risk prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Self-citationGuo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3795 · Cited by 880
Mostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
Self-citationPersistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0968 · Cited by 229 · cited 3×
“%) of 34 patients in the combined study cohorts had small-volume residual disease, defined as tumor volume 0.2 cm3 or less.19 In prior studies, achieving a nadir PSA below 0.2 ng/mL in 234 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY response to androgen suppression was associated with…”
BackgroundInfluentialSelf-citation
Cited by
Androgen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
Taplin, M.-E., Montgomery, B., Logothetis, C. J., Bubley, G. J., Richie, J. P., Dalkin, B. L., Sanda, M. G., Davis, J. W., Loda, M., True, L. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.4578 · Cited by 284
Self-citationBarnard, M., Quanson, J. L., Mostaghel, E., Pretorius, E., Snoep, J. L., & Storbeck, K.-H. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.06.013 · Cited by 72
“Primary tumor samples were from men enrolled in a previously published study of neoadjuvant androgen deprivation prior to prostatectomy in men with localized prostate cancer (T1c-T3, N0/NX) and Gleason score ≥ 7 [28].”
BackgroundSelf-citationRepurposing antifungal drugs for cancer therapy
Weng, N., Zhang, Z., Tan, Y., Zhang, X., Wei, X., & Zhu, Q. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.08.018 · Cited by 60
Zang, T., Tamae, D., Mesaros, C., Wang, Q., Huang, M., Blair, I. A., & Penning, T. M. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.08.001 · Cited by 29
Self-citation
Metadata
- Authors
- Mostaghel, E. A., Nelson, P. S., Lange, P., Lin, D. W., Taplin, M. E., Balk, S., Ellis, W., Kantoff, P., Marck, B., Tamae, D., Matsumoto, A. M., True, L. D., Vessella, R., Penning, T., Hunter Merrill, R., Gulati, R., & Montgomery, B.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-01-20
- Volume
- 32
- Issue
- 3
- Pages
- 229-237
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104530249
- Cited by
- 85
- References
- 4
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study. https://app.cochat.ai/papers/10.1200/jco.2012.48.6431
- The paper
- Mostaghel, E. A., Nelson, P. S., Lange, P., Lin, D. W., Taplin, M. E., Balk, S., Ellis, W., Kantoff, P., Marck, B., Tamae, D., Matsumoto, A. M., True, L. D., Vessella, R., Penning, T., Hunter Merrill, R., Gulati, R., & Montgomery, B. (2014). Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.48.6431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.